MHRA Authorises ApoC3 Inhibitor for Rare Lipid Disorder
The MHRA authorized Arrowhead Pharmaceuticals' plozasiran (Redemplo) to reduce triglycerides in adults with familial chylomicronaemia syndrome (FCS). A phase 3 trial showed an 80% median reduction in triglycerides with plozasiran vs. 17% with placebo. The drug is administered as a 25-mg subcutaneous injection every 3 months. Common side effects include hyperglycemia, headache, and nausea.
How this was made
The 30-second read
Why it matters
The approval could catalyze share price gains and encourage further regulatory submissions in other regions.
Market read
First regulatory clearance for an ApoC3 inhibitor, likely to affect biotech valuations and sector sentiment.
What to watch
Potential competition from other triglyceride‑lowering drugs and the small patient pool may limit revenue.
Background
Arrowhead's plozasiran targets a rare genetic disorder with no existing effective therapies, representing a niche but high‑need market.
Ticker impact
Arrowhead Pharmaceuticals received MHRA authorisation for its ApoC3 inhibitor plozasiran for familial chylomicronaemia syndrome.
upward pressure as investors price in potential sales and future approvals.
First‑time approval for a rare‑disease therapy, backed by strong Phase 3 data, creates immediate commercial opportunity.
Market effects
May spur interest in other ApoC3 inhibitors and rare‑disease biotech firms.
Positive for UK biotech sector and UK‑listed rare disease companies.
Highlights regulatory pathways for RNA‑based therapies globally.
Counterpoint
Approval is limited to the UK; broader commercial rollout may be slow, and reimbursement risk could temper upside.
Key entities
- CompanyArrowhead Pharmaceuticals
Developer of plozasiran, a RNAi therapeutic.
- RegulatorMHRA
UK Medicines and Healthcare products Regulatory Agency.
